Author

Kenneth E Palmer

University of Louisville - Cited by 5,134

Biography

 Kenneth E. Palmer is working as Professor in Department of Pharmacology and Toxicology and Owensboro Cancer Research Program, James Graham Brown Cancer Center, University of Louisville, USA. Kenneth E. Palmer international experience includes various programs, contributions and participation in different countries for diverse fields of study. Kenneth E. Palmer research interests reflect in wide range of publications in various national and international journals.  He completed his Ph.D in Microbiology in University of Cape Town in the year 1993. He is doing his research work in Biotechnology, Virology, Microbiology, HIV, AIDS, Vaccines.   
Title
Cited by
Year
Masitinib is a broad coronavirus 3CL inhibitor that blocks replication of SARS-CoV-2
N Drayman, JK DeMarco, KA Jones, SA Azizi, HM Froggatt, K Tan, ...Science 373 (6557), 931-936, 2021202
147
2021
Rapid detection of SARS-CoV-2 antibodies using electrochemical impedance-based detector
MZ Rashed, JA Kopechek, MC Priddy, KT Hamorsky, KE Palmer, N Mittal, ...Biosensors and Bioelectronics 171, 112709, 2021202
144
2021
Plant-derived exosomal microRNAs inhibit lung inflammation induced by exosomes SARS-CoV-2 Nsp12
Y Teng, F Xu, X Zhang, J Mu, M Sayed, X Hu, C Lei, M Sriwastva, ...Molecular Therapy 29 (8), 2424-2440, 2021202
69
2021
Cannabidiol inhibits SARS-CoV-2 replication through induction of the host ER stress and innate immune responses
LC Nguyen, D Yang, V Nicolaescu, TJ Best, H Gula, D Saxena, ...Science Advances 8 (8), eabi6110, 2022202
62
2022
Griffithsin inhibits Nipah virus entry and fusion and can protect Syrian golden hamsters from lethal Nipah virus challenge
MK Lo, JR Spengler, LRH Krumpe, SR Welch, A Chattopadhyay, ...The Journal of infectious diseases 221 (Supplement_4), S480-S492, 2020202
34
2020
Sustained-release Griffithsin nanoparticle-fiber composites against HIV-1 and HSV-2 infections
KM Tyo, AB Lasnik, L Zhang, M Mahmoud, AB Jenson, JL Fuqua, ...Journal of Controlled Release 321, 84-99, 2020202
31
2020
Impact of Q-Griffithsin anti-HIV microbicide gel in non-human primates: In situ analyses of epithelial and immune cell markers in rectal mucosa
G Günaydın, G Edfeldt, DA Garber, M Asghar, L Noȅl-Romas, A Burgener, ...Scientific reports 9 (1), 18120, 202
19
2019
Bullet comprising a compacted mixture of copper powder
M Sloff, B Benini, K GeistUS Patent 10,309,756, 2019201
16
2019
Bullet comprising a compacted mixture of copper powder
M Sloff, B Benini, K GeistUS Patent 10,309,756, 2019201
16
2019
Bullet comprising a compacted mixture of copper powder
M Sloff, B Benini, K GeistUS Patent 10,309,756, 2019201
16
2019
Induction of interferon response by high viral loads at early stage infection may protect against severe outcomes in COVID-19 patients
EC Rouchka, JH Chariker, B Alejandro, RS Adcock, R Singhal, J Ramirez, ...Scientific reports 11 (1), 7, 2021202
15
2021
Results of a phase 1, randomized, placebo-controlled first-in-human trial of griffithsin formulated in a carrageenan vaginal gel
N Teleshova, MJ Keller, JA Fernández Romero, BA Friedland, GW Creasy, ...PLoS One 17 (1), e0261775, 2022202
12
2022
Preformulation characterization of griffithsin, a biopharmaceutical candidate for HIV prevention
LF Kramzer, KT Hamorsky, PW Graebing, L Wang, JL Fuqua, N Matoba, ...Aaps Pharmscitech 22, 1-13, 2021202
10
2021
Rapid-release griffithsin fibers for dual prevention of HSV-2 and HIV-1 infections
KM Tyo, AB Lasnik, L Zhang, AB Jenson, JL Fuqua, KE Palmer, ...Antimicrobial agents and chemotherapy 64 (6), 10.1128/aac. 0213-1, 2020202
9
2020
Stability of plasmid and viral banks supporting the cGMP manufacture of Q-Griffithsin from a TMV-based viral vector
JM Corman, KT Hamorsky, JW Shepherd, E Hiatt, JL Fuqua, KE PalmerJournal of biotechnology 320, 74-76, 2020202
8
2020
Serological assessment of SARS-CoV-2 infection during the first wave of the pandemic in Louisville Kentucky
KT Hamorsky, AM Bushau-Sprinkle, K Kitterman, JM Corman, J DeMarco, ...Scientific reports 11 (1), 125, 2021202
8
2021
Public awareness of and support for the use of wastewater for SARS-CoV-2 Monitoring: A community survey in Louisville, Kentucky
RH Holm, JM Brick, AR Amraotkar, JL Hart, A Mukherjee, J Zeigler, ...Acs Es&T Water 2 (11), 1891-1898, 2022202
7
2022
In vitro study on synergistic interactions between free and encapsulated Q-griffithsin and antiretrovirals against HIV-1 infection
F Minooei, JR Fried, JL Fuqua, KE Palmer, JM Steinbach-RankinsInternational Journal of Nanomedicine, 1189-1206, 2021202
7
2021
Novel antifungal activity of Q-Griffithsin, a broad-spectrum antiviral lectin
HW Nabeta, JC Kouokam, AB Lasnik, JL Fuqua, KE PalmerMicrobiology Spectrum 9 (2), e00957-21, 2021202
6
2021
Pre-existing comorbidities diminish the likelihood of seropositivity after SARS-CoV-2 vaccination
AR Amraotkar, AM Bushau-Sprinkle, RJ Keith, KT Hamorsky, KE Palmer, ...Vaccines 10 (8), 133, 2022202
6
2022

Referred From: https://scholar.google.com/citations?user=aFPSGxAAAAAJ&hl=en&oi=ao

Cited by
Citations 5134
h-index 38
i10-index 68
Recommended Journals
Open Access Journals